The RECONNECT clinical trial is underway in Adelaide, Brisbane, Melbourne and Sydney, together with sites in the UK and in the US.  Participants aged 3-22 years old who have a confirmed diagnosis of Fragile X syndrome may be eligible to enrol in the trial.

The RECONNECT study is evaluating the effectiveness of Zygel, an investigational treatment produced by Zynerba Pharmaceuticals for some behavioural symptoms of Fragile X syndrome.

Zygel is a “pharmaceutically-manufactured cannabidiol, a non-euphoric cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.  Zygel is being developed for patients affected by Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q).”   [Source:  Zynerba website ]

The RECONNECT clinical trial site locations in Australia are:
ADELAIDE – Flinders Medical Centre
BRISBANE – Queensland Children’s Hospital
MELBOURNE – Fragile X Alliance Clinic
SYDNEY – Westmead Children’s Hospital